Glucose control during 3-month treatment with bihormonal artificial pancreas versus current diabetes care in patients after total pancreatectomy: study protocol for the PANORAMA randomized crossover trial

Patients undergoing total pancreatectomy (TP) will develop insulin-dependent diabetes, which is challenging to manage due to the complete absence of insulin and glucagon1. In recent years, the first European Commission-marked bihormonal artificial pancreas (BIHAP; Inreda Diabetic, Goor, the Netherla...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Lesemann, Charlotte A. (Verfasst von) , Veldhuisen, Charlotte L. van (Verfasst von) , Rompen, Ingmar F. (Verfasst von) , Bouwense, Stefan A. (Verfasst von) , Bosscha, Koop (Verfasst von) , Busch, Olivier R. (Verfasst von) , Dijkgraaf, Marcel G. W. (Verfasst von) , Eijck, Casper H. J. van (Verfasst von) , Haan, Job S. de (Verfasst von) , Haen, Roel (Verfasst von) , Hingh, Ignace H. J. de (Verfasst von) , Meijer, V. de (Verfasst von) , Nijkamp, Maarten W. (Verfasst von) , Mieog, J. Sven D. (Verfasst von) , Molenaar, I. Quintus (Verfasst von) , Santvoort, Hjalmar. (Verfasst von) , Stommel, Martijn W. J. (Verfasst von) , Voermans, Rogier P. (Verfasst von) , Wilmink, Johanna W. (Verfasst von) , De Vries, J. Hans (Verfasst von) , Besselink, Marc G. (Verfasst von)
Dokumenttyp: Article (Journal) Editorial
Sprache:Englisch
Veröffentlicht: February 2026
In: BJS open
Year: 2026, Jahrgang: 10, Pages: 1-2
ISSN:2474-9842
DOI:10.1093/bjsopen/zraf151
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/bjsopen/zraf151
Volltext
Verfasserangaben:Charlotte A Leseman, Charlotte L van Veldhuisen, Ingmar F Rompen, Stefan A Bouwense, Koop Bosscha, Olivier R Busch, Marcel GW Dijkgraaf, Casper HJ van Eijck, Job S de Haan, Roel Haen, Ignace HJ de Hingh, V de Meijer, Maarten W Nijkamp, J Sven D Mieog, I Quintus Molenaar, Hjalmar C van Santvoort, Martijn WJ Stommel, Rogier P Voermans, Johanna W Wilmink, J Hans De Vries and Marc G Besselink, on behalf of the Dutch Pancreatic Cancer Group
Beschreibung
Zusammenfassung:Patients undergoing total pancreatectomy (TP) will develop insulin-dependent diabetes, which is challenging to manage due to the complete absence of insulin and glucagon1. In recent years, the first European Commission-marked bihormonal artificial pancreas (BIHAP; Inreda Diabetic, Goor, the Netherlands) was introduced as a novel approach for the treatment of type 1 diabetes, with encouraging results2. Recently, the BIHAP was tested for the first time in patients after TP3. In a pilot study3, diabetes treatment with the BIHAP versus current diabetes treatment was compared in 10 patients after TP over a period of 7 days. This randomized crossover clinical trial demonstrated that the BIHAP can provide superior glucose control compared with current diabetes care (median time spent in range 78% (interquartile range (i.q.r.) 71-83%) versus 57% (i.q.r. 52-81%), respectively; P = 0.03).
Beschreibung:Online veröffentlicht: 20. Januar 2026
Gesehen am 25.03.2026
Beschreibung:Online Resource
ISSN:2474-9842
DOI:10.1093/bjsopen/zraf151